clinical trial · NCT06909253
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Myasthenia Gravis, GeneralizedRavulizumab
brief summary
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
started
May 15, 2025
primary completion
Dec 31, 2029
completion
Dec 31, 2029
last updated
May 15, 2026
detailed description
The Polish, prospective, multicenter, observational, cohort study designed to collect longitudinal data on the management and clinical outcomes of patients with gMG naive to complement inhibitors who received ravulizumab in the scope of routine clinical practice within the frames of National Drug Program (NDP) for up to 42 months (\~ 6 months baseline and \~36 months follow-up).
official title
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol